BACKGROUND: Killing of bacterial pathogens by granulocytes is a saturable process, as previously demonstrated. There is virtually no quantitative information about how granulocytes interact with antimicrobial chemotherapy to kill bacterial cells. METHODS: We performed a dose-ranging study with the aminoglycoside plazomicin against Pseudomonas aeruginosa ATCC27853 in a granulocyte-replete murine pneumonia model. Plazomicin was administered in a humanized fashion (ie, administration of decrementing doses 5 times over 24 hours, mimicking a human daily administration profile). Pharmacokinetic profiling was performed in plasma and epithelial lining fluid. All samples were simultaneously analyzed with a population model. Mouse cohorts were treated for 24 hours; other cohorts treated with the same therapy were observed for another 24 hours after therapy cessation, allowing delineation of the therapeutic effect necessary to reduce the bacterial burden to a level below the half-saturation point. RESULTS: The mean bacterial burden (±SD) at which granulocyte-mediated kill was half saturable was 2.45 × 10(6) ± 6.84 × 10(5) colony-forming units of bacteria per gram of tissue (CFU/g). Higher levels of plazomicin exposure reduced the bacterial burden to <5 log10 CFU/g, allowing granulocytes to kill an additional 1.0-1.5 log CFU/g over the subsequent 24 hours. CONCLUSIONS: For patients with large bacterial burdens (eg, individuals with ventilator-requiring hospital-acquired pneumonia), it is imperative to kill ≥2 log10 CFU/g early after treatment initiation, to allow the granulocytes to contribute optimally to bacterial clearance.
BACKGROUND: Killing of bacterial pathogens by granulocytes is a saturable process, as previously demonstrated. There is virtually no quantitative information about how granulocytes interact with antimicrobial chemotherapy to kill bacterial cells. METHODS: We performed a dose-ranging study with the aminoglycosideplazomicin against Pseudomonas aeruginosa ATCC27853 in a granulocyte-replete murinepneumonia model. Plazomicin was administered in a humanized fashion (ie, administration of decrementing doses 5 times over 24 hours, mimicking a human daily administration profile). Pharmacokinetic profiling was performed in plasma and epithelial lining fluid. All samples were simultaneously analyzed with a population model. Mouse cohorts were treated for 24 hours; other cohorts treated with the same therapy were observed for another 24 hours after therapy cessation, allowing delineation of the therapeutic effect necessary to reduce the bacterial burden to a level below the half-saturation point. RESULTS: The mean bacterial burden (±SD) at which granulocyte-mediated kill was half saturable was 2.45 × 10(6) ± 6.84 × 10(5) colony-forming units of bacteria per gram of tissue (CFU/g). Higher levels of plazomicin exposure reduced the bacterial burden to <5 log10 CFU/g, allowing granulocytes to kill an additional 1.0-1.5 log CFU/g over the subsequent 24 hours. CONCLUSIONS: For patients with large bacterial burdens (eg, individuals with ventilator-requiring hospital-acquired pneumonia), it is imperative to kill ≥2 log10 CFU/g early after treatment initiation, to allow the granulocytes to contribute optimally to bacterial clearance.
Authors: Mark R Deziel; Henry Heine; Arnold Louie; Mark Kao; William R Byrne; Jennifer Basset; Lynda Miller; Karen Bush; Michael Kelly; G L Drusano Journal: Antimicrob Agents Chemother Date: 2005-12 Impact factor: 5.191
Authors: M P Fink; D R Snydman; M S Niederman; K V Leeper; R H Johnson; S O Heard; R G Wunderink; J W Caldwell; J J Schentag; G A Siami Journal: Antimicrob Agents Chemother Date: 1994-03 Impact factor: 5.191
Authors: Arnold Louie; Weiguo Liu; Michael VanGuilder; Michael N Neely; Alan Schumitzky; Roger Jelliffe; Steven Fikes; Stephanie Kurhanewicz; Nichole Robbins; David Brown; Dodge Baluya; George L Drusano Journal: J Infect Dis Date: 2014-10-31 Impact factor: 5.226
Authors: Rajbharan Yadav; Cornelia B Landersdorfer; Roger L Nation; John D Boyce; Jürgen B Bulitta Journal: Antimicrob Agents Chemother Date: 2015-02-02 Impact factor: 5.191
Authors: Aaron J Heffernan; Fekade B Sime; Derek S Sarovich; Michael Neely; Yarmarly Guerra-Valero; Saiyuri Naicker; Kyra Cottrell; Patrick Harris; Katherine T Andrews; David Ellwood; Steven C Wallis; Jeffrey Lipman; Keith Grimwood; Jason A Roberts Journal: Antimicrob Agents Chemother Date: 2020-08-20 Impact factor: 5.191
Authors: Rajbharan Yadav; Jürgen B Bulitta; Roger L Nation; Cornelia B Landersdorfer Journal: Antimicrob Agents Chemother Date: 2016-12-27 Impact factor: 5.191
Authors: G L Drusano; Brandon Duncanson; C A Scanga; S Kim; S Schmidt; M N Neely; W M Yamada; Michael Vicchiarelli; C A Peloquin; Arnold Louie Journal: Antimicrob Agents Chemother Date: 2020-11-17 Impact factor: 5.191
Authors: Soon-Ee Cheah; Jian Li; Brian T Tsuji; Alan Forrest; Jürgen B Bulitta; Roger L Nation Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191